Literature DB >> 807603

Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration.

W Odio, E Van Laer, J Klastersky.   

Abstract

A crossover study was performed in five adult tracheotomized patients without respiratory tract disease to investigate the tracheobronchial kinetics of intramuscularly and endotracheally administered gentamicin in the absence of infection. Although intramuscular injection of 2 mg/kg of gentamicin yielded adequate levels in the serum, the concentrations in the bronchial secretions of noninfected patients were not adequate to inhibit strains of Pseudomonas aeruginosa isolated from other patients with clinical infections. Conversely, endotracheally administered gentamicin resulted in high and sustained concentrations in the bronchial secretions that were many times superior to the minimum bactericidal concentration of gentamicin against Pseudomonas aeruginosa. Gentamicin administered by aerosols resulted in concentrations within the bronchial secretions and sputum that were adequate to kill more than 90 per cent of the strains of Pseudomonas aeruginosa isolated in this hosopital. These studies suggest that endotracheally administered gentamicin might prove to be an adequate adjunct for the treatment of severe Pseudomonas infection of the tracheobronchial tract, particularly in the absence of foreight bodies and abnormalities of structure or function.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 807603     DOI: 10.1002/j.1552-4604.1975.tb01474.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  14 in total

Review 1.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

3.  Elevated tobramycin concentrations following endotracheal administration in a premature infant.

Authors:  Amanda Howard-Thompson; Michael L Christensen
Journal:  J Pediatr Pharmacol Ther       Date:  2008-04

4.  Quantification of amikacin in bronchial epithelial lining fluid in neonates.

Authors:  C Tayman; M N El-Attug; E Adams; A Van Schepdael; A Debeer; K Allegaert; A Smits
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

5.  Serum gentamicin concentrations during intratracheal administration.

Authors:  F Vogel; M Exner; H von Lilienfeld-Toal; N Cattelaens; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1984-05-02

6.  Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion.

Authors:  G Mombelli; L Coppens; J P Thys; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

7.  Systemic absorption of endotracheally administered aminoglycosides in seriously ill patients with pneumonia.

Authors:  S S Crosby; W A Edwards; C Brennan; E P Dellinger; L A Bauer
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

8.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

9.  Penetration of enoxacin into bronchial secretions.

Authors:  I W Fong; A Vandenbroucke; M Simbul
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 10.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.